We have located links that may give you full text access.
Living-Donor Kidney Transplant-Associated Thrombotic Microangiopathy Successfully Treated With Thymoglobulin: A Case Report.
Experimental and Clinical Transplantation 2019 January
Transplantation is the ultimate therapy for end-stage kidney disease. Early graft dysfunction is a devastating event to patients and carries risk of graft loss. Medical causes of early graft loss include graft rejection, drug toxicity, and thrombotic microangiopathy. Here, we report a case of posttransplant thrombotic microangiopathy associated with cellular vascular rejection. Thymoglobulin successfully reversed vascular rejection and thrombotic microangiopathy associated with half dosing of calcineurin inhibitors.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app